Company: SXTPW
Filing Date: 2025-06-06
Form Type: DRS
Source: 0001213900-25-052232
Chunk: 50

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-06-06
Form: DRS
Chunk 50
---
” as well as our financial statements and related notes appearing in our Annual Report on Form 10-K
for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the three months ended March 31, 2025, which are incorporated
by reference in this prospectus.

The information set forth below is illustrative only and
will be adjusted based on the actual public offering price and other terms of this offering determined at pricing.

|                                                                                                                                                                                                              |     | Actual |             |   |     | As          
 Adjusted(1) |
|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:-------|------------:|:--|:----|:------------|
| Cash, cash equivalents                                                                                                                                                                                       
 and short-term investments                                                                                                                                                                                   |     | $      |   3,451,500 |   |     | $           |
| Total long-term liabilities                                                                                                                                                                                  |     | $      |     146,502 |   |     | $           |
| Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized; 76,480 issued and outstanding as of March 31, 2025, actual,          issued and outstanding, as adjusted                           |     | $      |   9,567,439 |   |     | $           |
| Common stock, $0.0001 par value; 150,000,000 shares authorized at March 31, 2025; 1,472,891 shares issued and outstanding at March 31, 2025, actual;              shares issued and outstanding, as adjusted |     |        |         147 |   |     |             |
| Additional paid-in capital                                                                                                                                                                                   |     | $      |  36,821,588 |   |     | $           |
| Accumulated other comprehensive income                                                                                                                                                                       |     | $      |     125,567 |   |     | $           |
| Accumulated deficit                                                                                                                                                                                          |     | $      | (42,404,506 | ) |     | $           |
| Total stockholders’ equity                                                                                                                                                                                   |     | $      |   4,028,889 |   |     | $           |
| Total capitalization                                                                                                                                                                                         |     | $      |   4,175,391 |   |     | $           |

| (1) | The foregoing discussion and tables above are based on 1,472,891 shares of common stock outstanding